Will Johnson & Johnson Stock Reach $300 This Year?
With Johnson & Johnson stock hovering near mid-230s, investors are weighing if a $300 target is in reach this year as...
Examine the worst drawdowns for Dividend Aristocrats ETF and extract lessons to strengthen risk management in your portfolio.
9,644 articlesWith Johnson & Johnson stock hovering near mid-230s, investors are weighing if a $300 target is in reach this year as...
Two Harbors moved its special meeting to July 2 to push the CrossCountry Mortgage deal through, while a rival bid fro...
Market mood slides while retail spend stays resilient. Three beaten-down consumer stocks july look poised for catalys...
Carl Icahn’s latest stake move in Icahn Enterprises drew attention from investors. This article breaks down what icah...
Visa is more than a brand name. This article explores whether could buying visa stock make sense for long-term wealth...
Three cruise stocks rise and fall on 2025 results and 2026 guidance. This report weighs Royal Caribbean, Carnival, an...
Unpack GEO Group's Q1 2026 earnings through the transcript lens. Learn what drove revenue, how margins held up, and w...
The CAAP 2026 earnings call offers more than quarterly results. This guide breaks down revenue drivers, margins, and ...
Premium cardholders and broad payment networks offer two distinct paths to ride consumer spending. Explore how Americ...
IBM is shifting to a software-led model with accelerating cash flow and a higher dividend, signaling a durable, AI-ti...
Oil weakness adds pressure on Chevron as analysts weigh earnings visibility and cash returns. A rising risk of a drop...
Berkshire Hathaway’s cash pile nears the $400 billion mark, renewing scrutiny on what the conglomerate will do with v...